Multicell Technologies Stock

Multicell Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Multicell Technologies (MCET) as of Jul 20, 2026 is 286.35 %.

FCF Conversion

286.35 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Multicell Technologies is 2026 286.35 % . FCF Conversion Rate (FCF/EBITDA) of Multicell Technologies was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Multicell Technologies Stock analysis

What does Multicell Technologies do? Multicell Technologies Inc is a US-American company specialized in the development and production of innovative products in the field of biomedical and biotechnological research. The company was founded in 1987 by a team of scientists and has held a leading position in the industry ever since. They develop technologies for the isolation and artificial reproduction of cell cultures, collaborate with leading scientists and research institutions to develop new methods and products for fighting diseases such as cancer and cardiovascular diseases, and offer a wide range of products for biomedical and biotechnological research, including cell culture systems, antibody products, and specialized analysis tools. They also work on the production of cell lines and cultures and develop active therapeutics, including a program for developing a new therapeutic for multiple sclerosis. Additionally, they have a diagnostics business and have developed a special platform for DNA sequencing. Overall, Multicell Technologies Inc is known for its close collaboration with the scientific community and its dedication to developing innovative products for the medical field. Multicell Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Multicell Technologies stock

FCF Conversion Rate (FCF/EBITDA) of Multicell Technologies is 286.35 % in 2026.

Access this data via the Eulerpool API

Cash Flow — Multicell Technologies

All Key Metrics — Multicell Technologies